Assessing the Costs and Cost-Effectiveness of Genomic Sequencing

摘要: Despite dramatic drops in DNA sequencing costs, concerns are great that the integration of genomic into clinical settings will drastically increase health care expenditures. This commentary presents an overview what is known about costs and cost-effectiveness sequencing. We discuss cost germline sequencing, addressing factors have facilitated decrease to date anticipating drive future. then address diagnostic pharmacogenomic applications with emphasis on implications for secondary findings disclosure general patient care. Throughout, we ground discussion by describing efforts MedSeq Project, ongoing randomized controlled trial, understand integrating whole genome cardiology primary settings.